Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07157007 | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 | PHASE2 | RECRUITING | 90 | — | — | Sep 16, 2025 | Mar 1, 2026 | Jan 21, 2026 | 15 | Australia, South Korea +2 |
Adverse events incidence will be described using descriptive statistics methods
Adverse events severity will be assessed by current version of CTCAE
| Arm | Type | Description |
|---|---|---|
| Ratutrelvir (83-0060) non-randomised | EXPERIMENTAL | - |
| Paxlovid | ACTIVE_COMPARATOR | Standard of care |
| Ratutrelvir (83-0060) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ratutrelvir (83-0060) non-randomised | DRUG | 83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL) |
| Paxlovid | DRUG | Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor) |
| Ratutrelvir (83-0060) | DRUG | 83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL) |
Inclusion Criteria: 1. Confirmed SARS-CoV-2 infection for 120 h prior to randomization. 2. Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to randomization. 3. At least one of the symptoms attributable to COVID-19 present within 24 hours prior to the Day 1 with the seve...